Trials / Active Not Recruiting
Active Not RecruitingNCT06640049
A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China
A Phase 2, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer in China
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this study is to evaluate the effect of dostarlimab monotherapy in Chinese participants with locally advanced Mismatch-repair deficient (dMMR)/ Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Dostarlimab | Dostarlimab will be administered. |
Timeline
- Start date
- 2024-10-17
- Primary completion
- 2027-10-24
- Completion
- 2031-04-15
- First posted
- 2024-10-15
- Last updated
- 2025-11-17
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06640049. Inclusion in this directory is not an endorsement.